Summary

Paresthesia Treatment Market – Scope of Report
TMR’s report on the global paresthesia treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global paresthesia treatment market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global paresthesia treatment market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the paresthesia treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global paresthesia treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global paresthesia treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global paresthesia treatment market.

The report delves into the competitive landscape of the global paresthesia treatment market. Key players operating in the global paresthesia treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global paresthesia treatment market profiled in this report.

Key Questions Answered in Global paresthesia treatment Market Report
• What is the sales/revenue generated by paresthesia treatment across all regions during the forecast period?
• What are the opportunities in the global paresthesia treatment market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Paresthesia Treatment Market – Research Objectives and Research Approach
The comprehensive report on the global paresthesia treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global paresthesia treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global paresthesia treatment market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Paresthesia Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Paresthesia Treatment Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Paresthesia Treatment Market Analysis and Forecast, by Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type, 2020-2034
6.3.1. Acute Paresthesia
6.3.2. Chronic Paresthesia
6.4. Market Attractiveness, by Type
7. Global Paresthesia Treatment Market Analysis and Forecast, by Treatment
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Treatment, 2020-2034
7.3.1. Immunosuppressants
7.3.2. Anticonvulsants
7.3.3. Topical Creams
7.3.4. Antivirals
7.4. Market Attractiveness, by Treatment
8. Global Paresthesia Treatment Market Analysis and Forecast, by Indication
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Indication, 2020-2034
8.3.1. Radiculopathy
8.3.2. Neuropathy
8.4. Market Attractiveness, by Indication
9. Global Paresthesia Treatment Market Analysis and Forecast, by End-user
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2020-2034
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Attractiveness, by End-user
10. Global Paresthesia Treatment Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Paresthesia Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2020-2034
11.2.1. Acute Paresthesia
11.2.2. Chronic Paresthesia
11.3. Market Attractiveness, by Type
11.4. Market Value Forecast, by Treatment, 2020-2034
11.4.1. Immunosuppressants
11.4.2. Anticonvulsants
11.4.3. Topical Creams
11.4.4. Antivirals
11.5. Market Attractiveness, by Treatment
11.6. Market Value Forecast, by Indication, 2020-2034
11.6.1. Radiculopathy
11.6.2. Neuropathy
11.7. Market Attractiveness, by Indication
11.8. Market Value Forecast, by End-user, 2020-2034
11.8.1. Hospital Pharmacies
11.8.2. Retail Pharmacies
11.8.3. Online Pharmacies
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Type
11.11.2. By Treatment
11.11.3. By Indication
11.11.4. By End-user
11.11.5. By Country
12. Europe Paresthesia Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2020-2034
12.2.1. Acute Paresthesia
12.2.2. Chronic Paresthesia
12.3. Market Attractiveness, by Type
12.4. Market Value Forecast, by Treatment, 2020-2034
12.4.1. Immunosuppressants
12.4.2. Anticonvulsants
12.4.3. Topical Creams
12.4.4. Antivirals
12.5. Market Attractiveness, by Treatment
12.6. Market Value Forecast, by Indication, 2020-2034
12.6.1. Radiculopathy
12.6.2. Neuropathy
12.7. Market Attractiveness, by Indication
12.8. Market Value Forecast, by End-user, 2020-2034
12.8.1. Hospital Pharmacies
12.8.2. Retail Pharmacies
12.8.3. Online Pharmacies
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Type
12.11.2. By Treatment
12.11.3. By Indication
12.11.4. By End-user
12.11.5. By Country/Sub-region
13. Asia Pacific Paresthesia Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2020-2034
13.2.1. Acute Paresthesia
13.2.2. Chronic Paresthesia
13.3. Market Attractiveness, by Type
13.4. Market Value Forecast, by Treatment, 2020-2034
13.4.1. Immunosuppressants
13.4.2. Anticonvulsants
13.4.3. Topical Creams
13.4.4. Antivirals
13.5. Market Attractiveness, by Treatment
13.6. Market Value Forecast, by Indication, 2020-2034
13.6.1. Radiculopathy
13.6.2. Neuropathy
13.7. Market Attractiveness, by Indication
13.8. Market Value Forecast, by End-user, 2020-2034
13.8.1. Hospital Pharmacies
13.8.2. Retail Pharmacies
13.8.3. Online Pharmacies
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Type
13.11.2. By Treatment
13.11.3. By Indication
13.11.4. By End-user
13.11.5. By Country/Sub-region
14. Latin America Paresthesia Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2020-2034
14.2.1. Acute Paresthesia
14.2.2. Chronic Paresthesia
14.3. Market Attractiveness, by Type
14.4. Market Value Forecast, by Treatment, 2020-2034
14.4.1. Immunosuppressants
14.4.2. Anticonvulsants
14.4.3. Topical Creams
14.4.4. Antivirals
14.5. Market Attractiveness, by Treatment
14.6. Market Value Forecast, by Indication, 2020-2034
14.6.1. Radiculopathy
14.6.2. Neuropathy
14.7. Market Attractiveness, by Indication
14.8. Market Value Forecast, by End-user, 2020-2034
14.8.1. Hospital Pharmacies
14.8.2. Retail Pharmacies
14.8.3. Online Pharmacies
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Type
14.11.2. By Treatment
14.11.3. By Indication
14.11.4. By End-user
14.11.5. By Country/Sub-region
15. Middle East & Africa Paresthesia Treatment Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Type, 2020-2034
15.2.1. Acute Paresthesia
15.2.2. Chronic Paresthesia
15.3. Market Attractiveness, by Type
15.4. Market Value Forecast, by Treatment, 2020-2034
15.4.1. Immunosuppressants
15.4.2. Anticonvulsants
15.4.3. Topical Creams
15.4.4. Antivirals
15.5. Market Attractiveness, by Treatment
15.6. Market Value Forecast, by Indication, 2020-2034
15.6.1. Radiculopathy
15.6.2. Neuropathy
15.7. Market Attractiveness, by Indication
15.8. Market Value Forecast, by End-user, 2020-2034
15.8.1. Hospital Pharmacies
15.8.2. Retail Pharmacies
15.8.3. Online Pharmacies
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Type
15.11.2. By Treatment
15.11.3. By Indication
15.11.4. By End-user
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. Pfizer Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Novartis AG
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. GSK PLC
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Merck & Co., Inc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Johnson & Johnson
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Teva Pharmaceutical Industries Ltd.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. AbbVie Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Amgen Inc.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. AstraZeneca plc
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Bayer AG
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. Eli Lilly & Co.
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
16.3.12. Sanofi S.A.
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Product Portfolio
16.3.12.3. Financial Overview
16.3.12.4. SWOT Analysis
16.3.12.5. Strategic Overview